title: The effect of anaerobiosis on antistaphylococcal antibiotics.
abstract: The activity of eight antimicrobial agents which might be used in the treatment of staphylococcal osteomyelitis was tested under anaerobic conditions similar to those found in chronically infected bone. An agar-dilution method was employed to determine the minimum inhibitory concentrations of tobramycin, vancomycin, teicoplanin, ciprofloxacin, clindamycin, ceftriaxone, ticarcillin-clavulanic acid, and amoxicillin-clavulanic acid against 25 coagulase-positive and 25 coagulase-negative staphylococcal strains. The activity of tobramycin against coagulase-positive staphylococci, and of amoxicillin-clavulanic acid and ticarcillin-clavulanic acid against coagulase-negative staphylococci was markedly decreased with anaerobiosis. Vancomycin, teicoplanin, and ciprofloxacin were active against coagulase-positive and coagulase-negative staphylococci under both aerobic and anaerobic conditions. It was also found that antibiotic concentrations comparable to the high levels which might be achieved with local antibiotic therapy of osteomyelitis were not sufficient to overcome the level of resistance (100 micrograms/ml) of staphylococci which were not susceptible to tobramycin, clindamycin, ceftriaxone, and ticarcillin-clavulanic acid.
authors.affiliation: Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415.
authors.forename: D T
authors.initials: DT
authors.lastname: Tsukayama
authors.forename: D R
authors.initials: DR
authors.lastname: Guay
authors.forename: R B
authors.initials: RB
authors.lastname: Gustilo
authors.forename: B
authors.initials: B
authors.lastname: Wicklund
authors.forename: R
authors.initials: R
authors.lastname: Gruninger
authors.forename: P K
authors.initials: PK
authors.lastname: Peterson
mesh_terms: D000658:Amoxicillin / Q000494:pharmacology; D019980:Amoxicillin-Potassium Clavulanate Combination; D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002443:Ceftriaxone / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D003030:Coagulase / Q000096:biosynthesis; D004359:Drug Therapy, Combination / Q000494:pharmacology; D006020:Glycopeptides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology; D017334:Teicoplanin; D013982:Ticarcillin / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D003030:Coagulase; D006020:Glycopeptides; D002981:Clindamycin; D002939:Ciprofloxacin; D017334:Teicoplanin; D014640:Vancomycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D002443:Ceftriaxone; D000658:Amoxicillin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D014031:Tobramycin